Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5265MR)

This product GTTS-WQ5265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5265MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10364MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ3296MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ1083MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ11098MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ1491MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ404MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ4770MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2975MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW